Browsing: Biosciences

Merida’s antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune function

SARASOTA, Fla.–(BUSINESS WIRE)–Belenos Biosciences, Inc. (“Belenos”), a clinical-stage biotechnology company developing long-acting bispecific antibodies for chronic inflammatory diseases, today announced that ‘512 met its primary and all secondary endpoints in a double-blind, placebo-controlled Phase 2 clinical study in adults with inadequately controlled CRSwNP (NCT06930612). ‘512 is known as BEL512 ex-China and CM512 in Greater China

MENLO PARK, Calif.–(BUSINESS WIRE)–Adaptyx Biosciences, a Stanford University spinout developing a wearable biosensing platform capable of measuring multiple biomarkers continuously and simultaneously, today announced a study to identify an objective molecular signature of chronic pain, conducted with Attune Neurosciences and funded through the Advanced Research Projects Agency for Health’s (ARPA-H) EVIDENT program. The 24-month, $4…

CNBC Cures is proudly under AstraZeneca Rare Disease, whose support enables our journalism to elevate stories that advance research, innovation and patient care in rare diseases

Neurocrine Biosciences (NBIX) has drawn fresh attention after announcing a Phase 1 first in human study of NBIP 1968, a triple agonist candidate aimed at obesity treatment and intended for once weekly subcutaneous dosing

Adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1+ epilepsy

Aug. 7, 2026 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-‘1968, an investigational GLP-1/GIP/glucagon receptor triple agonist being developed as a therapy for obesity

Accomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic Disorders

Spruce Biosciences (Nasdaq: SPRB) has appointed Adrian Quartel, M.D., FFPM, as chief medical officer, strengthening its executive leadership as the late-stage biopharmaceutical company advances tralesinidase alfa enzyme replacement therapy (TA-ERT) toward a planned Biologics License Application (BLA) filing in the fourth quarter of 2026

I initiate coverage of MBX Biosciences (MBX) with a speculative buy rating. My thesis is substantiated by two-pillars: firstly, canvuparatide is a clinically de-risked, and once-weekly